Bosh sahifaDRUG • CNSX
add
Bright Minds Biosciences Inc
Yopilish kursi
123,14 $
Kunlik diapazon
116,92 $ - 122,82 $
Yillik diapazon
33,01 $ - 170,00 $
Bozor kapitalizatsiyasi
1,15 mlrd CAD
Oʻrtacha hajm
740,00
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
CNSX
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (CAD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | — | — |
Joriy xarajat | 6,74 mln | 325,10% |
Sof foyda | -7,57 mln | -15 349,58% |
Sof foyda marjasi | — | — |
Har bir ulushga tushum | -0,97 | -9 800,00% |
EBITDA | — | — |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (CAD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 89,05 mln | 53,80% |
Jami aktivlari | 90,88 mln | 55,62% |
Jami passivlari | 1,60 mln | 179,80% |
Umumiy kapital | 89,28 mln | — |
Tarqatilgan aksiyalar | 9,79 mln | — |
Narxi/balansdagi bahosi | 10,74 | — |
Aktivlardan daromad | -19,23% | — |
Kapitaldan daromad | -19,65% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (CAD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -7,57 mln | -15 349,58% |
Operatsiyalardan naqd pul | -5,82 mln | -289,18% |
Sarmoyadan naqd pul | — | — |
Moliyadan naqd pul | 13,39 mln | -74,27% |
Naqd pulning sof oʻzgarishi | 6,14 mln | -88,23% |
Boʻsh pul | -4,01 mln | -339,54% |
Haqida
Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use.
It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens.
The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York. Wikipedia
Tashkil etilgan
2017
Xodimlar soni
26
